1stOncology™: Cancer Intelligence Service – Page 333 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Huonslab Secures Patent for ADC Subcutaneous Formulation Incorporating ‘HyDIFFUZE™’ Platform

On July 27, 2026 Huonslab, the R&D subsidiary of Huons Group (KOSDAQ:084110), reported that it has secured a patent covering a subcutaneous (SC) formulation of an Antibody-Drug Conjugate (ADC) incorporating its proprietary human-derived hyaluronidase-based platform technology, HyDIFFUZE.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

An ADC is a targeted therapeutic combining a monoclonal antibody, which delivers therapeutic agents to target cells such as cancer cells, with a cytotoxic drug. Recently, the global ADC market has been expanding rapidly across diverse indications.

Currently approved ADCs are all administered via intravenous (IV) infusion, driving demand for SC formulation to improve patient convenience and healthcare efficiency. Because ADCs are structurally complex biologics, the development of SC formulations requires advanced formulation technologies capable of simultaneously ensuring stability at high concentrations and efficient subcutaneous drug delivery.

The newly granted patent covers ADC SC formulation technology utilizing the HyDIFFUZE platform to enable therapeutics development.

Through formulation studies, Huonslab confirmed that HyDIFFUZE-enabled ADC SC formulations maintained excellent physicochemical stability even at high concentrations. In nonclinical pharmacokinetic (PK) evaluations, the formulations showed a faster increase in plasma concentrations following SC administration. Compared to formulations without HyDIFFUZE, systemic drug exposure (AUC) and peak plasma concentration (Cmax) increased by up to 126% and 149%, respectively.

Based on this study, Huonslab expects HyDIFFUZE-enabled ADC SC formulations to improve early absorption following subcutaneous administration and enhance systemic drug exposure.

The findings were presented at the ASCPT Annual Meeting in March. With the patent registration, Huonslab has also secured intellectual property rights covering core technologies for ADC SC formulations.

"This patent is meaningful because it demonstrates the applicability of the HyDIFFUZE platform to ADCs while expanding its potential applications," a Huonslab official said. "We will continue to advance the platform technology and broaden its application across next-generation biopharmaceuticals."

Meanwhile, Huonslab is seeking marketing authorization from Korea’s Ministry of Food and Drug Safety (MFDS) within this year for HYDIZYME Injection, its standalone recombinant hyaluronidase product. In addition, the HyDIFFUZE platform continues to expand its application to next-generation biopharmaceuticals, including ADCs.

(Press release, Huons Global, JUL 27, 2026, View Source [SID1234669443])

DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101

On July 27, 2026 DifGen Pharmaceuticals LLC reported that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application and issued a "study may proceed" letter for DFGN-101, an intramuscular injection under development for the treatment of advanced or metastatic breast cancer in women.

DFGN-101 is designed to be administered as a single intramuscular injection, compared with the two separate injections required for the currently marketed reference product. If approved, the product would reduce the number of injections a patient receives at each treatment visit.

Under the agreed development pathway, DifGen will proceed with preclinical toxicology studies in rat and rabbit and a Phase 1 pharmacokinetic study. A clinical endpoint/efficacy study is not required. The Agency’s position was supported by the company’s Chemistry, Manufacturing and Controls (CMC) data package and by results from a pilot pharmacokinetic study showing a PK profile comparable to that of the reference product.

The clearance reflects DifGen’s formulation and clinical development capabilities and its focus on identifying efficient development pathways for technically complex programs.

(Press release, DifGen Pharmaceuticals, JUL 27, 2026, View Source [SID1234669442])

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

On July 27, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) reported that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid tumors. This marks the Company’s first dual-payload ADC to enter the clinical stage.

SKB565 is developed using the Company’s proprietary OptiDC platform. Featuring an innovative dual-payload design, SKB565 enables the direct delivery of toxins and immunomodulators, two kinds of payload with complementary mechanisms of action, to tumor tissue. Compared with conventional ADCs carrying only toxins, SKB565 has a dual antitumor mechanism: it precisely targets and kills tumors while activating the immune system within the tumor microenvironment to elicit an antitumor immune response, bringing enhanced and more durable antitumor efficacy. In preclinical studies, SKB565 demonstrated excellent antitumor activity and safety, with its outstanding therapeutic potential to support further clinical development.

Leveraging technological expertise and platform advantages in the ADC field, Kelun-Biotech has established a diversified pipeline of innovative molecules featuring high-value targets, differentiated designs, and global potential. Building on this foundation, the Company continues to advance its "ADC + IO" strategy—on one hand by actively exploring high-quality combination regimens, including multiple ongoing clinical studies evaluating ADCs in combination with PD-(L)1 monoclonal antibodies, as well as the PD-1/VEGF bispecific antibody SKB118 in combination with its proprietary ADC portfolio; on the other hand, the Company is advancing integrated drug design strategies by incorporating synergistic functional components into a single ADC molecule.

Dr. Michael Ge, CEO of Kelun-Biotech, said, " SKB565 is one of the core representative drugs of our integrated ‘ADC + IO’ strategy, leveraging the synergistic mechanism of its dual payloads to enhance efficacy and overcome drug resistance. Dual-payload ADCs are emerging as one of the key next-generation innovations in the ADC field. The advancement of SKB565 into clinical stage not only marks an important milestone in the achievements transformation of our technology platform, but also substantiates the continued deepening of our innovation capabilities in ADCs. We will actively advance the clinical development of novel drug conjugates such as SKB565, striving to deliver greater benefits to patients with cancer as soon as possible."

(Press release, Kelun, JUL 27, 2026, View Source [SID1234669441])

Everest Medicines Announces Participation in Upcoming Investor Conferences

On July 27, 2026 Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, reported that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences.

Morgan Stanley Biotech Without Borders Series
Date: Tuesday, July 28, 2026
Time: US: 10:00am – 10:30am ET / 10:00pm – 10:30pm HKT
Format: Fireside chat
Webcast: View Source;tp_key=ca5039df5f

2nd Annual Evercore China Biotech Summit
Date: Tuesday, August 18, 2026
Time: 11:00am HKT
Format: Presentation and Q&A
Location: The Ritz-Carlton Shanghai, Pudong

(Press release, Everest Medicines, JUL 27, 2026, View Source [SID1234669440])

Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

On July 27, 2026 Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, reported that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd. ("Sinopharm"). The two parties will establish the Sinopharm – Harbour BioMed Innovation Consortium (the "Innovation Consortium") to advance collaborative research and development of innovative biologics.

Under the terms of the agreement, Harbour BioMed and Sinopharm will collaborate across the full research and development lifecycle of innovative biologics, with a strategic focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas. Harbour BioMed will leverage its globally leading Harbour Mice fully human antibody technology platform and AI-enabled drug discovery capabilities to drive the discovery and optimization of antibody candidates together with Sinopharm. Sinopharm will contribute their expertise in clinical development, large-scale manufacturing and commercialization, and will be responsible for developing commercial-scale manufacturing processes, producing clinical trial materials, and commercializing products arising from the collaboration. The two parties will jointly fund the research and development activities and share product rights in accordance with mutually agreed terms.

"We are delighted to establish this strategic partnership with Sinopharm," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. "Harbour BioMed is committed to becoming a leading platform-driven biopharmaceutical group. Leveraging our globally differentiated Harbour Mice fully human antibody technology platform and continuously expanding AI-enabled antibody discovery capabilities, we have established strategic collaborations with leading global pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Pfizer. This partnership with Sinopharm represents another important step in advancing our ‘platform + pipeline’ strategy in China. Sinopharm is a leading pharmaceutical and healthcare group that covers the entire industry chain—from R&D and manufacturing to distribution. With strong R&D capabilities, robust industrial-scale production capacity, proven commercial execution, and an extensive market network, we look forward to deeply integrating the strengths of our technology platform with Sinopharm’s full-industry-chain capabilities to jointly accelerate the R&D and accessibility of innovative medicines."

Sinopharm commented: "As the national team in the pharmaceutical and healthcare sector, Sinopharm has always placed scientific and technological innovation at the core of its development strategy and is accelerating the establishment of a new paradigm that synergizes independent innovation with open collaboration. Harbour BioMed is a world-leading platform-driven biopharmaceutical company, equipped with a rare fully human antibody technology platform and AI-powered antibody discovery capabilities that are at the forefront in China. The establishment of an innovation R&D consortium with Harbour BioMed represents a key move by Sinopharm to optimize resource allocation and enhance R&D efficiency. We look forward to both parties fully leveraging our respective strengths in technology, talent, platforms, and industrial chains to jointly advance the R&D and industrialization of innovative drugs, and to provide patients with more high-quality and affordable treatment options."

(Press release, Harbour BioMed, JUL 27, 2026, View Source [SID1234669439])